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Abstract 
Successful antiretroviral therapy (ART) depends on appropriate use of antiretroviral agents; 
which ultimately prevents replication of Human Immunodeficiency Virus (HIV) thus 
delaying clinical progression of the disease. This study explored how HIV status disclosure 
affects adherence to antiretroviral therapy at Mamelodi Hospital, using a convenience 
sampling method with a sample size of 50 adults above 18 years who were on treatment for a 
minimum of two years prior to the study.  
An interview protocol was used to uncover patients’ demographics, sexual orientation, and 
HIV status disclosure, adherence to antiretroviral drugs, drug side effects, how often they 
missed their doses and how HIV status disclosure / non-disclosure affected their adherence to 
treatment. Patients’ medical records were assessed to validate and correlate the information 
obtained from the interviews. The scientific test results used were the CD4count and Viral 
loads which are used to monitor the HIV/AIDS disease progression. 
All partakers involved in the study made their HIV status known and reported taking their 
medicines regularly. The patients’ CD4 count and VL were verified, the CD4 count has 
shown an upward trend while the VL load showed a downward trend in keeping with patients 
who are adhering to ART. 
The majority of participants (54% or 27 patients) reported they had never skipped taking their 
medication. The participants also reported they had taken their medicine in front of other 
people and they constituted 74% (37) of the group. Of this 74%, 78.38% (29 patients) said it 
was because they had disclosed their status. This observation supports the fact that if you 
have disclosed your HIV status, you have better chances of adhering to prescribed 
medication.  
Findings from the study at Mamelodi Hospital revealed that for as long as one has disclosed 
their HIV status, the outcome of treatment adherence will be better. The only shortfall noted 
was lack of partakers who did not divulge their HIV status thus a comparison could not be 
done. It was acknowledged that some participants in the study might have reported disclosure 
of their HIV status to be in good favour of the researcher to create an impression that they are 
adhering to their medication. The study has confirmed the existence of a relationship between 
HIV status disclosure and adherence to ART.  
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Opsomming 
 
Suksessvolle antiretrovirale terapie (ART) hang af van die toepaslike gebruik van 
antiretrovirale middels, wat replikase van die MI-virus verhoed, en dus die kliniese vordering 
van die siekte vertraag. Hierdie studie het ondersoek hoe die bekendmaking van MIV-status 
die gehoorsaamheid tot ART beïnvloed het by die Mamelodi Hospitaal. ‘n Gerieflikheid-
streekproef met ‘n groote van 50 volwassenes bo 18 jaar is gebruik en die deelnememers 
moes ten minste vir twee jaar voor die studie reeds op behandeling gewees het. 
 
Data is deur middel van onderhoude ingesamel, met die doel om pasiënte se demografiese 
inligting, seksuele orientasie, MIV-status, gehoorsaamheid tot ART en newe-effekte van 
ART in te samel. Pasiënte se mediese rekords is nagegaan om die inligting wat uit die 
onderhoude verkry is te bevestig. Die wetenskaplike toetse wat gebruik is, was die CD4-
telling en virale lading wat gebruik word om MIV/Vigs te monitor. 
 
Al die deelnemers het hul MIV-status bekend gemaak en aangedui dat hul hul medikasie 
gereeld gebruik. Die pasiënte se CD4-tellings en virale lading is bevestig, die CD4-tellings 
het ‘n opwaartse neiging getoon terwyl die virale lading ‘n afwaartse neighing getoon het. 
 
Die meerderheid van die deelnemers (54%) het aangedui dat hul nog nooit hul medikasie 
oorgeslaan het nie. 74% van die deelnemers het aagedui dat hul hul medikasie voor ander 
mense neem -  hul noem dat dit as gevolg van die feit is dat hul hul status bekend gemaak het. 
Dit ondersteun die feit dat mense wie hul status bekend maak beter kanse het om gehoorsaam 
hul medikasie te gebruik. 
 
Die studie by die Mamelodi Hospitaal toon dat solank mense hul MIV-status bekend maak, 
hul meer gehoorsaam is teenoor die gebruik van hul medikasie. Die studie bevestig dus die 
verband tussen bekendmaking van MIV-status en gehoorsaamheid tot ART. 
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CHAPTER ONE 
1.1. Introduction 
Human Immunodeficiency Virus (HIV) is a chronic disease that eventually results in 
Acquired Immune Deficiency Syndrome (AIDS) and death unless managed appropriately 
with antiretroviral therapy (Wilson, Cotton, Better, Meyer, Venter & Martens, 2008, p. 514).  
Successful antiretroviral therapy depends on appropriate use of antiretroviral agents; which 
ultimately prevents replication of HIV thus delaying clinical progression of the disease. There 
is a positive relationship between antiretroviral adherence and maintaining suppression of the 
virus. Non-adherence to antiretroviral therapy leads to poor suppression of the virus and the 
emergence of drug resistant viral strains that ultimately reduces the treatment options.  
In the public health approach to antiretroviral therapy advocated by the World Health 
Organisation, adopted by most resource-limited countries including South Africa, only two 
sequential antiretroviral regimens are available. With limited antiretroviral options available, 
it is particularly important for antiretroviral programmes in Southern Africa to achieve high 
levels of adherence. 
To avoid the possibility of the HIV virus evolving to a resistant strain, an adherence of 100% 
to all treatment regimens should be achieved. Wilson et al. has defined 95% adherence as 
skipping more than 3 doses of a twice daily treatment plan in a calendar month. This 
decreases the intended objective of viral suppression. The achievement of a 95% adherence 
level in HIV is onerous, since in other chronic diseases the levels are considerably lower than 
95% (Wilson et al. 2008, p. 514). 
In Sub-Saharan Africa the reported challenges hindering optimal drug adherence includes 
HIV status nondisclosure, stigma, excessive use of alcohol and complicated drug regimen 
(Bartlett, Gallant & Conradie, 2008).  
Mills, Nachega, Buchen, Orbinski, Attaran, Sing, Rachlis, Wu, Cooper, Thabane, Wilson, 
Guyatt & Bangsberg, 2006) reported that a greater number of patients on ART who have 
made their status known to family and friends adhere to their regimen far better than those 
that have not disclosed their status. Educating and promoting HIV status disclosure in a 
community with ART availability may culminate in increased uptake of Voluntary Testing 
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and Counselling (VCT), resulting in reduction of stigma which subsequently enhances drug 
adherence (Mills et al., 2006). 
Inconsistent intake of antiretroviral therapy has dire consequences like opportunistic 
infections, , antiretroviral drug resistance, increase in HIV infection rate,  rapid progression to 
AIDS and ultimately premature death (Mills et al., 2006). 
1.2. Mamelodi Hospital Profile 
Mamelodi Hospital opened its doors in May 1981 as a community health centre. In October 
1985 it got a hospital status operating 24 hours with 30 post natal beds, 30 short stay ward 
beds and 30 cradle beds. Mamelodi Hospital is situated on the eastern side of the Tshwane 
Metsweding District, serving the following outlying areas to the east of Mamelodi: Eersterus, 
Cullinan, Donkerhoek, Rayton, Boschkop, Bronkhorspruit, Pretoria East, Silverton and East-
Lynn. The hospital serves a population of about 1,1million people. 
Apart from rendering services to people residing in the above mentioned areas, the hospital 
will from time to time treat cross-border patients from Mpumalanga, Limpopo, Mozambique 
and Zimbabwe. 
Currently Mamelodi Hospital has 281 beds and is earmarked for 400 beds. Health services 
provided by the hospital are organised along the service principles of the Gauteng 
Department of Health with the focus on access and delivering improved quality of service for 
all the communities. 
The referral clinics include Stanza Bopape Community Healthcare Center, Phahameng 
Clinic, Holani Clinic, Mamelodi West Clinic, Cullinan Rehabilitaion Centre, Refilwe Clinic, 
Ekangala Community Healthcare Centre, Rayton Clinic and Bronkhorspruit Hospital (Public 
Private Partnership). 
Mamelodi Hospital provides a 24 hour emergency service that includes Casualty, Maternity 
(delivery and post-natal), In-patient care, Medico-Legal services, Operating Theatre and X-
Rays. 
Out Patient Services that are provided are General Outpatient Department (OPD) and 
speciality clinics that include Family Medicine, Ophthalmology, Ear Nose and Throat (ENT), 
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General Surgery, Orthopaedics, Obstetrics and Gynaecology, Paediatrics, Psychiatry, 
Medical Male Circumcision (MMC) and Antiretroviral Therapy Clinic (ART).  
The hospital also provides Allied Medical Services such as Pharmacy, Psychology, 
Physiotherapy, Occupational Therapy, Social Work, Optometry, Human Nutrition and 
Radiography. 
1.3. Research Problem 
Mamelodi Hospital ART clinic in the last three years has been seeing an average of 20 487 
patients per annum. In 2011 they had 110 recorded treatment defaulters, in 2012 they had 34 
and in 2013 they had 13 treatment defaulters. There have been a declining number of 
treatment defaulters over the years that could probably be associated with an increased 
number of patients that have disclosed their HIV status. 
HIV status disclosure is an important aspect of HIV prevention and treatment. Many studies 
were done by Mills et al. (2006); Nachega, Stein, Lehman, Hlatshwayo, Mothopeng, 
Chaisson, and Karstaedt, (2004) and Nakiyemba, Aurugai, Kwasa, and Oyabba (2006), have 
demonstrated that there is an interdependence between disclosure of HIV status and 
adherence to therapy. It is for this reason that more scholars should investigate and have an 
opinion on the effect HIV status disclosure has on adherence to antiretroviral treatment. In 
this study we are going to make an attempt to come out with an opinion regarding the effect 
HIV status disclosure has on adherence to antiretroviral therapy. 
I do not know what the effect of HIV status disclosure is to the adherence of antiretroviral 
therapy at Mamelodi Hospital. 
1.4. Research Question 
How does HIV status disclosure affect adherence to antiretroviral therapy at Mamelodi 
Hospital? 
1.5. Significance of the Study 
The data gathered will contribute to a pool of knowledge that is available to prevent and treat 
HIV disease effectively. The study will benefit patients and healthcare providers in the fight 
against the HIV pandemic, patients will be empowered with the necessary information and 
assist in creating the necessary support structures for patients to adhere to antiretroviral 
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therapy. The overall benefit to patients is improved quality of life while on antiretroviral 
therapy. 
1.6. Aims and Objectives of the Study 
The study aims to establish the relationship and effects of HIV status disclosure on adherence 
to antiretroviral therapy at Mamelodi Hospital. 
1.6.1. Objectives 
a. To identify whether patients who are on ART have disclosed their status. 
b. To ascertain adherence to ART 
c. To provide guidelines to support patients who are on ART in dealing with HIV status 
disclosure. 
1.7. Methodology 
The research will be conducted in a large group of patients at the Mamelodi Hospital 
Antiretroviral Therapy clinic. The sample size for the study will be 50 patients. They will be 
drawn from a population using the convenience sampling method. Patients who are 18 years 
and older and on antiretroviral therapy for more than 2 years (since May 2011) meet the 
criteria of inclusion.  
A consent form will be signed by all participants selected prior to commencement of the 
study. An interview protocol will include the following topics: 
a. Patient demographics 
b. Sexual orientation 
c. HIV status disclosure 
d. Adherence to antiretroviral drugs 
e. Drug side effects 
f. How often they miss their doses 
g. How does HIV status disclosure / non – disclosure affect their adherence to treatment. 
Patients’ medical records will be assessed to validate and correlate the information obtained 
from the interviews. This will be done with scientific test results e.g. CD4 and viral loads 
used to monitor the HIV/AIDS disease progression. The data for the study will only be 
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collected after all permission letters have been received from the Research Ethics committee 
at Stellenbosch University, Mamelodi Hospital’s CEO and the Gauteng Department of 
Health. At the end of the study, all information will be analysed and interpreted using 
descriptive statistical methods and a conclusion will be drawn from the results. 
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CHAPTER TWO 
LITERATURE REVIEW 
2.1. Introduction 
The literature covered focuses on the three aspects that affect Antiretroviral Therapy (ART) 
adherence namely HIV Disclosure, Stigma and Drug Adherence. There is no consensus about 
the relationship between HIV status disclosure and drug adherence, as it will be demonstrated 
in the discussions that will follow. Drug cost, HIV status non-disclosure, stigma, alcohol 
abuse and the multiple drug regimens have been reported to affect drug adherence (Bartlett et 
al., 2008). 
2.2. Definition of Concepts 
2.1.1. HIV status disclosure 
Rabkin, EL-Sadr and Abrams (2005) define disclosure of HIV status as letting people know 
about the individual’s HIV status.  The HIV status is always known to self (following an HIV 
test) and that is why disclosure can be regarded as the process that leads to the act of telling 
rather than just the act of telling.  A person that is HIV positive, once informed of their HIV 
positive – status, generally keeps the information to him- or herself and debates the issues 
around telling or not telling before finally deciding to disclose their status (Levy, Laska, 
Abelhauser, Delfraissy, Goujard, Boue and Darmont, 1999, p 1041; Petrak, Doyle, Smith, 
Skinner and Hedge, 2001, p. 70). 
2.1.2. HIV stigma 
HIV, like many other chronic conditions such as Diabetes Mellitus, carries a stigma with it. 
HIV stigma is affected by many factors including culture, gender, socio economic status and 
literacy.  Social rejection and condemnation of HIV/AIDS infected people has always been a 
major factor contributing to the pandemic (UNAIDS, 2006). People Living with HIV and 
AIDS (PLHA) dread being stigmatized and discriminated thus reducing their ability to 
exercise prevention, undergo VCT, divulge their HIV status to others, seek medical attention 
and moral support as well starting and adhering to ART (UNAIDS 2006). Goffman (1963), 
defined stigma as a deeply discrediting attribute that results in dishonouring a person. He 
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further noted that stigma decreases life opportunities due to discriminatory actions. The 
concept of discrimination is not treated as a separate entity from stigma.  
2.1.3. Drug adherence 
Drug adherence refers to the act of patients taking their medication according to their 
prescription (e.g. taking medication 3 times a day) for the required duration. (Circulation. 
2009; 119: 3028-3035). According to the above definition, the patient has a choice to agree or 
disagree to take the prescribed medication and both the patient and the healthcare provider 
must work together to establish treatment goals and the medical regimen. 
In Antiretroviral therapy, Drug Adherence is very crucial as the degree of adherence 
determines the success of viral suppression and therefore the desired health outcomes and 
quality of life of people living with HIV/AIDS. 
It is important to understand the scientific facts regarding HIV infection before attempting to 
unravel the effects of HIV status disclosure on Antiretroviral Therapy Adherence. 
2.1.4. HIV diagnosis 
HIV diagnosis is achieved through voluntary counselling and testing (VCT). This is a two-
stage process starting with counselling of the individual to be tested and followed by testing 
of the person. 
2.1.5. Counselling 
HIV counselling intends to: 
 provide a supportive environment 
 help clients manage their problems and issues 
 explore coping skills that clients have used before and help them to develop new ones 
 empower clients to become self-sufficient in dealing with emerging issues and 
problems 
 counsel HIV-negative clients so that they know how to remain negative 
 counsel HIV-positive clients on how to avoid re-infection and how to prevent 
infecting others 
 Explore options with clients that will help to bring about necessary changes in 
behaviour (e.g. abstinence, monogamy, i.e. mutual and faithfulness and the correct 
use of condoms) (Wilson et al., 2008). 
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2.1.6. HIV testing 
Most clinical settings rely on antibody testing to make an accurate diagnosis of an HIV 
infection. The World Health Organisation (WHO) testing recommendations for regions 
where HIV prevalence exceeds 10% approves the use of two different enzyme-linked 
immunosorbent assay (ELISA) tests or two different rapid tests on site to confirm HIV 
infection. At lower HIV prevalence, a three-test strategy is recommended. Almost all ELISA 
and rapid tests are designed to detect both HIV-1 and HIV-2 antibodies. 
There are several types on HIV diagnostic tests in the market namely: 
 Enzyme-linked Immunosorbent Assay (ELISA) 
 Rapid test devices 
 The Western blot test 
 The p24 antigen 
 Polymerase Chain Reaction (PCR) 
 Culture 
2.1.7. The window period 
Window period refers to a time lag after infection by HIV wherein sero-conversion takes 
place. During this period there is a delay in the detection of antibodies in the blood. This 
diagnostic “window period” is approximately four weeks. Tests for the virus itself reveal the 
infection somewhat earlier. The p24 antigen test is positive in the majority of patients a week 
before antibody ELISA tests becomes reactive. PCR testing can detect HIV in the blood from 
approximately two weeks after infection (Wilson, et al., 2008) 
2.1.8. HIV disease monitoring 
There are two important HIV disease monitoring tests, the viral load and the CD4 count. An 
analogy has been made comparing the information these two tests bring to the parameters of 
a train journey: the viral load measures the speed of travel of the train; the CD4 count 
indicates the distance from the crash, while the crash indicates the onset of AIDS. Therefore, 
viral load predicts the rate of disease progression (rate of loss of CD4 cells) and the CD4 
count indicates the stage of disease that the patient has already reached (Wilson, et. al., 2008). 
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2.1.9. HIV viral load 
The viral load refers to the concentration of free virus in the blood plasma. It is important to 
note that HIV is an RNA virus and therefore all commercially available viral load tests 
measure HIV RNA and the assays available are for only HIV-1. 
 There are three main types of viral load tests: quantitative PCR; 
 nucleic acid sequence based amplification (NASBA) and 
 branch- chain DNA assay 
These tests are equally reliable and can detect free HIV in the range of fifty to 1 million 
copies per millilitre of serum and the results are copies of virus/ml, or as a log value. 
2.1.10. CD4 count 
CD4 count is an important test that gives us the information about the stage of the disease as 
already discussed above. Our immune system has T-lymphocytes which constitutes our cell 
mediated immunity. The T-lymphocytes have T-cell receptors that are also referred to as CD3 
molecules. CD4 is a molecule found on the surface of helper T-lymphocytes. There’s another 
molecule the CD8 found on the cytotoxic T-lymphocytes. Both the CD4 and CD8 molecules 
play a subsidiary role in the binding of CD3 to MHC-II and MHC-I respectively, during 
antigen presentation. The CD4 molecule is the major receptor for HIV, and CD+ T-
lymphocytes are the main target of HIV infection and they are directly and indirectly 
destroyed by HIV. Initially early in the disease the CD4 has a high turnover replacing the 
cells as quickly as they are destroyed, but over time as the disease progresses, the 
regenerative capacity of the immune system gets exhausted, with the resultant drop in the 
total CD+ cells. 
The CD4 cells are the pillars of the immune system and they act by centrally stimulating the 
immune system upon exposure to infections, and their drop in number will therefore correlate 
with an increasing degree of immune suppression. 
The CD4 cells are detected using the monoclonal antibodies to the CD4 molecule. A 
fluorescent-activated cell sorter (FACS) machine is commonly used to count them (Wilson et 
al., 2008). 
2.1.11. Antiretroviral therapy 
Antiretroviral therapy reduces the occurrence of opportunistic diseases and decreases short-
term mortality from HIV infection. Its cost–effectiveness, particularly in relation to the 
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prevention of mother-to-child transmission, has been demonstrated in both developed and 
developing nations. Furthermore, it has been shown to be able to be implemented in resource 
poor settings (Spencer, 2005, p4). 
The overall survival with untreated HIV-1 infection is approximately 10 – 12 years. This 
appears to hold for communities in the industrialized regions of the world. Survival is slightly 
worse for those in resource-poor nations. In a study of rural Ugandans, the median time from 
sero-conversion to death with AIDS was 9.8 years. Estimated survival in 10 European 
countries has increased with the use of Highly Active Antiretroviral Therapy (HAART) 
(Spencer, 2005, p4). 
Antiretroviral therapy suppresses but does not cure HIV, so therapy is lifelong (Wilson, et al., 
2008). Highly Active Antiretroviral Therapy (HAART) is a combination of at least three 
antiretroviral drugs from different classes. 
2.1.12. Goals of therapy 
The clinical goals are to improve quality of life and increase life expectancy. The virologic 
goal is to get viral load reduction to < 50 c/ml (cells/millilitre).  The immunologic goal 
focuses on achieving reconstruction of the immune system indicated by the increase in the 
number of CD4 cells towards the normal range. The therapeutic goals are aimed at 
rationalising drug sequencing in a manner that will accomplish the previously mentioned 
goals, sustaining treatment options, preventing drug toxicity and facilitating adherence. The 
ultimate objective is to achieve the epidemiological goal of reducing HIV transmission 
(Bartlett, Gallant, Conradie, 2008, p.38).  Good compliance with medication is the basis of 
good viral control. 
2.1.13. Classes of antiretroviral agents 
Antiretroviral drugs are classified in the main by their site and mechanism of action. To get a 
clear picture of this classification we must first review the HIV life-cycle; the events are 
illustrated on the following page with the diagrammatic presentation of the events on page 
12. 
Specific events in the life cycle of HIV: 
1. Free virus (HIV) 
2. Fusion with CD4 receptor and cell membrane 
3. Penetration and entry of HIV into cytoplasm of cell 
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4. “Uncoating” of the virus and liberation of “free” virus and its associated viral 
enzymes 
5. Transformation of viral RNA into viral DNA: Reverse Transcription 
6. Penetration of nucleus of the cell and integration of viral DNA into host(genomic) 
DNA Integration 
7. Activation of the CD4 cell leads to the transcription of proviral DNA into its original 
(genomic) viral RNA and messenger, mRNA: Viral Transcription 
8. Viral RNA leaves the nucleus together with viral mRNA. mRNA is translated into 
appropriate viral proteins (structural, enzymic) on the ribosomes of the endoplasmic 
reticulum: Translation 
9. Translated viral proteins and genomic viral RNA are processed, assembled, packaged 
and released in the form of new infectious virus: New viral assembly. 
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Figure 1: Diagrammatic representation of HIV Life Cycle: (Spencer, 2005) 
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Anti –retroviral therapies directed to the viral life cycle: 
Drug 1: HIV- entry inhibitors 
Drug 2: Reverse –transcriptase inhibitors 
Drug 3: Integrase Inhibitors 
Drug 4: Protease Inhibitors (PI’s) 
HAART involves the use of at least 3 different antiretroviral drugs: historically, two 
nucleoside reverse transcriptase inhibitors (NRTI’s) together with a protease inhibitor (PI), 
but now also taken to 2 NRTIs with a non-nucleoside reverse transcriptase inhibitor 
(NNRTIs). These are used in combination. Three NRTI’s used together generally do not 
constitute HAART (e.g. zidovudine, lamivudine and abacavir). This combination has been 
shown to possess inferior antiretroviral activity when compared to HAART (Spencer, 2005, 
p14). 
2.1.14. HIV –entry inhibitors 
HIV entry inhibitors are not widely used in the treatment of HIV.  An example is a drug 
called T20 Enfurvirtide (ENF) (Fuzeon) manufactured by Roche. This drug is not available in 
the developing nations. 
2.1.15. Reverse Transcriptase Inhibitors 
Nucleoside reverse transcriptase inhibitors 
This class of drugs are essentially the nucleoside analogues and they resemble the natural 
nucleotide building blocks of DNA and block the conversion of viral RNA into proviral 
DNA. NRTI’s are pro-drugs that need to be activated intracellularly by tri-phosphorylation 
(Wilson, et al., 2008). Examples in this class are: didanosine, stavudine, zidovudine, 
lamivudine, abacavir, tenofovir and emtricitabine. 
Non-Nucleoside reverse transcriptase inhibitors 
NNRTIs do not bind at the active site of reverse transcriptase, but cause a conformational 
change in the enzyme that inhibits it. There are two NNRTIs that are currently available, 
Efavirenz and Nevirapine. These drugs have a long half-life (Wilson, et al, 2008.). 
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2.1.16. Protease Inhibitors 
This class of drugs interfere with the HIV protease enzyme, which cleaves transcribed viral 
polyproteins into functional proteins. Inhibition of protease results in the release of immature 
non-infectious viral particles. Small doses of ritonavir markedly increase the plasma 
concentrations and prolong the half–lives of most PI’s. This is known as ritonavir boosting 
and has become the standard of care for administering these agents (Wilson, et al., p466, 
2008) 
2.1.17. Integrase Inhibitors 
Drugs in this class of antiretroviral agents have not yet been approved for commercial use. 
Several are undergoing clinical investigation (Spencer, 2005, p20). 
2.3. Who HIV Staging 
The revised WHO clinical staging of HIV in adults and adolescents is divided into clinical 
stages according to the severity of the illness. There are four clinical stages starting with the 
asymptomatic stage 1 until you get to clinical stage 4 with opportunistic infections where a 
preliminary diagnosis can be made on the basis of clinical signs or simple investigations; see 
details in appendix F. 
2.4. National Guidelines for Antiretroviral Therapy  
The standardized national eligibility criteria for initiation of ART for both adolescents and 
adults in South Africa are based on CD4 count and presence or absence of opportunistic 
infections. All HIV positive pregnant or breastfeeding women should be immediately 
initiated on ART irrespective of their CD4 count to prevent mother to child transmission. In 
general patients who have a CD4 count of <350 c/ml must be initiated on ART. For more 
details on the initiation and ART regimen see appendix G. 
2.5. Literature Discussion 
Global HIV/AIDS medicine (UNAIDS, 2008, p. 207) states that approximately 39.4 million 
people are living with the HIV, An estimated 90% of those living with the virus reside in 
developing countries. Sub-Saharan Africa is home to 25.4 million people infected with 
HIV/AIDS, rendering it the hardest hit region.  Virtually 14.4 million people globally require 
antiretroviral therapy however about 8 million of these were receiving treatment as of 2011 
(UNAIDS Global Report, 2012).  Unavailability of resources to treat HIV has posed a great 
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concern worldwide; this has been handled by many organizations and funding bodies 
internationally as an emergency. The reduction in cost of medication, monitoring of CD4 
counts and viral loads accompanied by a surge in international funders’ support has 
significantly increased access to therapy.  
Despite the efforts of trying to amplify the spectrum of HIV treatment to all affected, a great 
concern of resistance against antiretroviral therapy has developed.  Information from first 
world countries suggests that up to 10% of new infections and 50% of existing infections 
have resistant strains of the virus, negatively affecting treatment response (UNAIDS, 2008). 
It is very important to prevent the emergence of resistant viral strains in under developed 
countries due to restricted availability of second line regimens (UNAIDS, 2008). 
It can be anticipated that drug resistance will occur in improper utilization antiretroviral 
treatment seeing as the HIV virus will not be suppressed. Socio-economic factors play a 
major role in poor adherence to therapy and worldwide spread of the drug resistant virus 
(UNAIDS, 2008).  
There was concern from different circles regarding the ability of patients from disadvantaged 
communities to achieve the requisite heights of adherence necessary to suppress the virus to 
prevent the development of HIV resistant virus. Others are proponents of a view that calls for 
the establishment of adherence programmes to prepare patients in such communities to be 
ready for large scale antiretroviral rollouts to prevent drug resistance. There is a growing 
amount of evidence with a differing view that suggests that disadvantaged communities have 
better adherence outcomes than their developed counterparts (Global HIV/AIDS Medicine, 
2008). 
The high HIV prevalence in Sub Saharan Africa has attracted a lot of interest from many 
scholars who focused their studies to this region. A number of researchers did studies in the 
poor countries with inadequate resources and the majority of the countries are in Sub Saharan 
Africa. The results of their studies revealed that drug adherence levels of more than 90% 
were achieved (Global HIV/AIDS Medicine, 2008). 
 Orrell (2008) showed in phase 3 studies conducted at a public hospital’s ART clinic, with a 
sample size of 289 participants over a period of 48 weeks. The pill count at the clinic method 
was used and the results found that over 93.5% drug adherence was achieved. Similar studies 
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were done in Senegal where adherence levels of 91% were attained and in Uganda where 
adherence levels of between 91 to 94 % were achieved (Orrell, 2008). 
In another study conducted in Kampala, Uganda in a mother to child transmission program, 
they used a different method of unexpected pill count. Their findings revealed adherence 
levels of between 97.3 – 99.8% (Byakika-Tusiime, Oyugi, Tumwikirize, Katabira, Mugyenyi 
and Bangsberg, 2005). 
 Clinical trials done at different facilities in Cameroon used a sample size of 60 patients using 
ART for the first time. A self-reported adherence method was employed and yielded an 
average adherence level of 99% (Byakika et al., 2005).  
A common observation gathered from adherence studies in Sub-Saharan Africa suggests that 
the results are comparable to that of the well developed countries.  This observation is 
further supported by two independent studies done in South Africa. In one study with a large 
sample size of 7812 participants in a private sector HIV/AIDS disease management 
programme, the adherence levels were reported to be more than 70% for 3908 participants. In 
the other study done in the public sector clinic in Soweto using a small sample size of 66 
participants, the reported results revealed that 88% of the participants reported a 95% 
adherence (UNAIDS, 2008). 
According to global HIV/AIDS medicine, challenges associated with non-adherence are 
experienced in both disadvantaged and advantaged settings. Challenges noted are alcohol 
abuse, medication intolerance due to regimen complexity, psychosocial elements, psychiatric 
conditions, young age, male gender forgetfulness working away from home with very busy 
schedules and marital status (UNAIDS, 2008). 
However, disadvantaged settings have their own specific challenges such as language barrier, 
occasional unavailability of medicine and high costs, treatment centres situated far from 
patients’ homes as well as stigma (UNAIDS, 2008).  
In many disadvantaged communities stigma plays a significant role in non-adherence to 
treatment. In the Soweto study chances of obtaining more than 95% adherence diminished 
with an increased fear of being stigmatized (UNAIDS, 2008). Only 15 % of patients in the 
Botswana study have cited stigma as a major obstacle in adherence to medication. 
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There are high levels of illiteracy noted in disadvantaged communities amongst HIV infected 
populations which makes it difficult to attain high levels of adherence (UNAIDS, 2008). 
Speaking a different language from health care facility staff negatively influences adherence 
to therapy (Orrel, Byakika-Tusiime and Bangsberg, 2008).   
Stigma is the biggest challenge in HIV prevention and treatment which lead to non-adherence 
to antiretroviral therapy. Many studies have shown that because of fear of stigmatisation, 
people infected with HIV taking ARV’s fear to disclose their HIV status and as a result, they 
become less adherent to their ART.  Rabkin, EL-Sadr and Abrams (2005) define disclosure of 
HIV status as letting people know about the individual’s HIV status. 
Once a person who is HIV positive is informed of their HIV-positive status, they generally 
keep the information to themselves and debate the issues around telling or not telling before 
she/he finally decides to disclose their status (Levy, Laska, Abelhauser, Delfraissy, Goujard, 
Boue and Darmont, 1999, p1041; Petrak, Doyle, Smith, Skinner and Hedge, 2001, p70). 
HIV infected individuals prefer not to divulge their status to their partners, others and even 
healthcare providers for fear of stigmatisation and discrimination. Disclosure of HIV and 
adherence to ART can affect each other in several important ways as an individual taking 
ART could be identified as being HIV positive through others recognizing the tablets (forced 
disclosure) due to public awareness regarding the treatment. 
 Side effects caused by ART may also serve as a proxy for disclosure. In an effort to keep the 
secret about their HIV status, this may result in patients disguising their medication and or 
changing treatment. This could adversely affect adherence to their ART medication 
(Klitzmen, Kirshenbaum, Dodge, Remien, Ehrhart, Johnson, Kittel, Daya, Morin, Kelly, 
Lightfoot and Rotheram–Borus, 2004). 
Studies done by Mills et al. (2006); Nachega et al., (2004) and Nakiyemba, Aurugai, Kwasa, 
and Oyabba (2006), support the existence of a clear relationship between HIV status 
disclosure and adherence to antiretroviral therapy, but Skhosana, Struther, Gray, and 
McIntyre (2006) argue that in a study conducted amongst antiretroviral users in Johannesburg 
South Africa, there was no direct relationship between disclosure of HIV status and 
adherence to ART.  
The relationship between disclosure of HIV status and adherence clearly depends on the 
perception of both the patients and the person the information is disclosed to. Fear of being 
Stellenbosch University  https://scholar.sun.ac.za
18 
 
stigmatised has often been reported as barrier to adherence to medication as this prevented 
patients from disclosing their HIV status and therefore losing out on social support (Skhosana 
et al., 2006). On the other hand in some instances, non-disclosure appeared as a facilitator of 
adherence (Ateka, 2006, p493-496; Nachega et. al, 2006, p.5131-5132, Nakiyemba et. al, 
2006, p294; Skhosana et al., 2006, p20). 
2.6. Summary of the Main Findings 
There is genuine global concern about the emergence of drug resistant HIV strains and there 
is consensus that this is a result of poor adherence (UNAIDS, 2008). Data from the developed 
world indicates that up to 10% of new infections and 50% of prevalent infections carry 
resistant virus, which compromises treatment response (UNAIDS, 2008). 
Stigma remains an important problem in many resource-limited settings. Stigma has been 
associated with non-adherence in Soweto and Botswana (UNAIDS, 2008).  It is an interesting 
observation to note how stigma influences HIV status disclosure with secondary impact on 
drug adherence. A total of 15% of patients in the Botswana study claimed that stigma 
interfered with their ability to take medication (UNAIDS, 2008). 
There’s no consensus about the relationship between HIV status disclosure and drug 
adherence as it has been shown in several studies. However many authors has shown 
convincingly that such a relationship exist. Studies done by Mills et al. (2006), Nachega et 
al., (2004), support the existence of a clear relationship between HIV status disclosure and 
adherence to antiretroviral therapy. 
I remain unconvinced by Skhosana et al. (2006), who argued that in a study conducted 
amongst antiretroviral therapy users in Johannesburg South Africa, there was no direct 
relationship between disclosure of HIV status and adherence to ART. Their argument that the 
relationship between disclosure of HIV status and adherence to ART depends on the 
perception of both the patients and the person the information is disclosed to, is not reason 
enough to support their argument. 
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CHAPTER THREE 
RESEARCH DESIGN AND METHODOLOGY 
3.1. Introduction 
This is a cross sectional study that was conducted at Mamelodi Hospital Antiretroviral Clinic 
(ART) on 50 patients during a period between 06 March 2014 and 03 April 2014. The 
patients were selected using a convenience sampling method as they attended the clinic for 
their routine checkup during the specified period. See the annexures of the following 
documents: informed consent, interview protocol, Ethics Review Committee (Stellenbosch 
University) permission letter, and permission letters from Gauteng Department of Health and 
Mamelodi Hospital CEO. 
The Epistemiological approach in the study follows studying and analysis of data collected 
from previous studies done in the subject. The original data collected in this study will be 
analyzed and compared with the findings of the earlier studies. The approach in this study is 
evidence based. My positionality in the study as a researcher does not seem to threaten or 
intimidate the study participants. The participant’s perception of the researcher is that of 
someone who has a potential to improve their treatment and their lives as the researcher is not 
their regular caregiver. 
3.2. Aims and Objectives of the Study 
The aim of the study is to establish the relationship and effects of HIV status disclosure on 
adherence to antiretroviral therapy at Mamelodi Hospital. 
The objectives of the study include the following: 
 To identify whether patients who are on ART have disclosed their status. 
 To ascertain adherence to ART 
 To provide guidelines to support patients who are on ART in dealing with HIV status 
disclosure. 
3.3. Study Design 
This is an empirical research study, where data will be collected, analysed, reported and the 
results interpreted accordingly (Christensen, Burke, Turner, 2011, p. 54).  
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The study design is more convenient because it allows for data to be collected from 
participants in a single brief period. The participants were recruited during their normal clinic 
visits for their routine medical check-up. This approach did not create an inconvenience for 
participants as it did not require extra, special visits. 
A structured interview method was used to collect data from the research participants and the 
patient records were studied to correlate information gathered from the interview with actual 
patient’s information on their file. The information used concerned patients’ CD4 counts and 
viral loads. The CD4 and the viral loads were assessed to ascertain whether there was indeed 
an increase in the CD4 count and a corresponding viral suppression to support the patients 
claims that they were adhering to the treatment or to the contrary. In an interview, a trained 
interviewer asks research participants questions and records the responses. 
The survey instrument used in interviewing looks much like a questionnaire, but it is given a 
more specialized label of interview protocol. The primary difference between a questionnaire 
and an interview protocol is that a questionnaire must be written so that participants can 
easily complete it without the aid of anyone. An interview protocol is a survey instrument 
that has been put into a script-like format so that the interviewer can systematically read the 
questions and easily record participants’ responses. Interviews are generally preferred to 
questionnaires because the researcher has more control over data collection and can probe 
participants for follow- up responses (Christensen et al., 2011, p337). 
The face-to-face method that was used, as the name suggests, is a person-to-person interview. 
This technique has the advantages of allowing the interviewer to clear ambiguities in the 
question asked and to probe further clarification of responses if the interviewee provides an 
inadequate answer. This method generally provides a higher completion rate and more 
complete respondent information. The primary weakness of this method is that it is the most 
expensive. It is also possible that the interviewer might bias the responses. For example, an 
interviewer might (either consciously or unconsciously) spend more time and probe more 
effectively with an attractive or especially interesting interviewee, resulting in biased results. 
Interviewer training can help interviewers learn how to conduct effective interviews to 
minimize any problems of this sort (Christensen et al., 2011, p337). 
The sampling of participants in this study, was done using convenience sampling, where you 
simply ask people who are most available or the most easily selected to participate in a 
research study (Christensen et al., 2011, p158) 
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The study is a survey research. Survey research is a widely used type of non-experimental 
research.  It is a research method where individuals fill out a questionnaire or are interviewed 
about their attitudes, activities, optional and beliefs (Christensen et al., 2011, p330).  The 
questionnaire or interview protocol is usually standardised to present each research 
participant with the same stimulus (i.e. questions, directions).  Survey research is oftentimes 
conducted with a sample selected from a target population of interest (Christensen et al., 
2011, p330).  Survey research can probe into a given state of affairs that exists at a given time 
as well as follow up changes over time (Christensen et al., 2011, pp330 – 331). 
A sample is a set of elements drawn from a population. Sampling is a process of drawing a 
sample from a population. A population is a full set of elements from which a sample is 
selected (Christensen et al., 2011, p150). Since the study is empirical, the preferred method of 
sampling is the convenience sampling method, where you simply ask people who are most 
available or the most easily selected to participate in a research study. Convenience sampling 
falls under non-random sampling techniques, which tend to be weaker sampling methods, but 
sometimes they are necessary because of practical considerations (Christensen et al., 2011, 
p158). 
A sample size of 50 participants was selected according to the inclusion and exclusion 
criteria:  any patient who is 18 years and older and has been on ART for more than two years. 
The size of the sample was 50 because of the limited resources available for the study i.e. 
budget, time and human resources. 
3.4. Methodology (Data Collection) 
The research was conducted in a large group of patients at the Mamelodi Hospital 
Antiretroviral Therapy clinic.  The sample size for the study was 50 patients who were drawn 
from a population using the convenience sampling method.  The inclusion criteria were 
patients who are 18 years and older who have been on antiretroviral therapy for more than 2 
years, i.e. at least since May 2011. 
Consent was obtained from the selected participants and all participants signed the consent 
forms before commencing the study.  The consent form was presented to them in English or 
translated to their vernacular languages by the researcher. The interview protocol used 
included the following: 
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1. Patient demographics 
2. Sexual orientation 
3. HIV status disclosure 
4. Adherence to antiretroviral drugs 
5. Drug side effects 
6. How often they miss their doses 
7. How does HIV status disclosure/non–disclosure affect their adherence to treatment? 
The data collection process started on 06 March and ended on 07 April 2014. The researcher 
was allocated one of the consulting rooms where the interviews were conducted. The study 
was conducted during the normal clinic visits, the participants were recruited by the nursing 
staffs that were trained about the study protocol. The researcher obtained consent from the 
participants who were willing to participate in the study. The consent was obtained in English 
and translated into either Sotho/Tswana or Zulu for those who did not fully understand 
English.  An interview protocol was used to collect data from participants and their responses 
were recorded. 
After the data collection process was concluded, the data was captured using the Excel 
computer software. The data was then transferred to a statistical software program (STATA) 
for data cleaning, editing, analysis and statistical computing in order to minimise error. Since 
the study is empirical in nature, like many other survey studies, the descriptive statistical 
method of analysing the data was used. Frequency distributions were used to analyse the data 
collected. A frequency distribution is a systematic arrangement of data values in which the 
unique data values are order ranked and the frequencies are provided for each of these values. 
Oftentimes, the percentages for each frequency are also included in a frequency distribution 
(Christensen, et al., 2011, p393). 
Measures of Central Tendency techniques were also used to describe the data collected. A 
measure of central tendency is the single numerical value that is considered most typical of 
the values of a quantitative variable. Measures of central tendency can be described in three 
different ways: the mode, mean and the median. The commonly used ones are the mean and 
the median. The mode is the most frequently occurring number for a variable. The mean is 
the name researchers use to refer to the arithmetic average. The median is the center point in 
a set of numbers that has been arranged in ascending or descending order. If you have an odd 
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set of numbers, the median is the middle. If you have an even number of numbers, the median 
is the average of the two centremost numbers (Christensen, et al., 2011, p399-400). 
Measures of Variability are also used in descriptive statistics. A measure of variability is 
defined as the numerical index that provides information about how spread out or how much 
variation is present in a variable. Range is the highest or largest number minus the lowest or 
smallest number in a set of numbers. The variance is the average deviation of the data values 
from their mean in “square units”. The variance can be turned into more meaningful units, 
e.g., the Standard Deviation. The standard deviation (i.e. the square root of the variance) is an 
approximate indicator of the average distance that your data values are from their mean. 
Variance and standard deviation are the two most popular measures of variability. They are 
superior to the range because they take into account all of the data values for a variable and 
they both provide information about the dispersion or variation around the mean value of a 
variable (Christensen et al., 2011, p402). 
In descriptive statistics it is often helpful to use graphical presentations of data to 
communicate the research findings. There are a number of graphs that can be used give a 
pictorial representation of the data. Graphical representations can be used for one or more 
variables. Examples of graphic representations of data include the following: Bar graphs, 
Histograms, Line graphs and Scatterplots. 
3.5. Shortcomings and Limitations of Data 
The data collected during the interviews is of good quality. The participants were all 
interested and eager to give more information as they perceived the study as a necessary 
intervention in the fight against the HIV pandemic. The sample size was small and therefore 
will pose challenges when we want to generalize the findings of the study to the whole 
population. The data collected from the patients’ files were often incomplete e.g., missing 
CD4 count results and in other instances missing viral load results. The patients’ records in 
most public hospitals are not held up to standard. 
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CHAPTER FOUR 
RESEARCH RESULTS 
4.1. Introduction 
The study was conducted on 50 participants at Mamelodi Hospital Antiretroviral Clinic 
during the period March to April 2014. Of the 50 participants, 62% were female and 38% 
were males. The age varied between 26 and 62 years with the mean age of 42.12 and standard 
deviation of 9.2. The majority of the participants were heterosexual with only one 
homosexual. 
The participants had their first year of diagnosis spread between 1992 and 2012. The mean 
year of diagnosis was 2007.46 and standard deviation of 3.49. One percent of participants 
were diagnosed in 1992 and 50 percent by 2010. The majority of participants, 78%, started 
treatment in their first year of diagnosis. The participants that were diagnosed in 1992 started 
treatment after seventeen years. 
Ninety four percent of the study candidates were voluntarily diagnosed while only 6% were 
involuntarily diagnosed. Of the 50 participants, only 2 % reported that they did not receive 
pre and post-test counseling and 94% of the participants reported that they found counseling 
to be helpful while only 6% did not realize the value of counseling. 
4.2. CD4 Count and Viral Load Measurements Analysis 
During an average follow-up period of 7 years, 216 CD4 count and 193 viral load (VL) 
measurements were collected from the fifty participants. Table 1 and 2 below demonstrates 
the average CD4 count and log viral loads measured at 11 different time points. Baseline 
CD4 counts of 241.8 with SD = 226.02 is the lowest compared to other follow-up CD4 
counts. The trend sharply increases from baseline CD4 count to the next CD4 count and 
steadily increases over time. This can be observed on the graphs presented on page 27 - 28.  
Table 1 Time point in years for CD4 count and viral load analysis 
 1 2 3 4 5 6 7 8 9 10 11 
Time point 
(years) 
0 1.1 1.82 2.64 3.33 4.31 5.25 5.86 5.94 6.33 7 
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Table 2 Mean CD4 counts and their corresponding standard deviations at different time 
points 
Variable Observation Mean Standard 
Deviation 
Minimum Maximum 
Cd4count1 50 241.8 226.0201 2 930 
Cd4 count 2 45 366.2667 250.3322 14 1307 
cd4 count 3 37 383.6757 216.5191 26 933 
Cd4 count 4 31 400.9677 189.4442 31 901 
cd4 count 5 20 471 209.6144 36 831 
cd4 count 6 12 545.8333 350.7778 28 1394 
cd4 count 7 9 431.2222 317.8887 46 1089 
cd4 count 8 6 413 324.2678 27 799 
cd4 count 9 4 559.5 330.368 90 801 
cd4 count 10 1 701 . 701 701 
cd4 count 11 1 970 . 970 970 
 
Table 3 Mean log viral load and their corresponding standard deviations at different 
time points 
Variable Observation Mean Standard 
Deviation 
Minimum Maximum 
 
Logvl1 48 5.89495 4.059199 2.890372 14.91412 
Logvl2 43 4.270039 2.578309 2.995732 13.03054 
Logvl3 33 3.880572 2.068957 2.995732 10.81122 
Logvl4 24 3.490057 1.703258 2.995732 11.20601 
Logvl5 14 3.781037 1.700146 2.995732 9.191463 
Logvl6 13 4.285002 2.573454 2.995732 10.84704 
Logvl7 10 3.589235 1.87682 2.995732 8.930758 
Logvl8 5 5.972615 4.251658 2.995732 12.14713 
Logvl9 2 2.995732 0 2.995732 2.995732 
Logvl10 1 2.995732 . 2.995732 2.995732 
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Figure 2: Discriptive analysis of CD4 count measurements over a period of time for 
participants that disclosed their HIV status. Note that, everyone disclosed their HIV status in 
this study. 
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Figure 3: Descriptive analysis of viral load measurements over a period of time for 
participants that disclosed their HIV status. Note that the average log viral load (VL) count at 
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baseline (time0) was 5.89495, 4.270039 at time1 (i.e., 1.1 year later), 3.880572 at 2.6 years, 
2.995732 after 7 years. Refer to table 3 above for further details. 
4.3. HIV Status Disclosure 
All research participants reported voluntary disclosure of their HIV status.  The participants 
differed in people to whom they disclosed to for various reasons and why they disclosed their 
HIV status .Table 4 shows the distribution of the people to whom the participants have 
disclosed to. 
Table 4 Frequency distribution of person(s) disclosed to. The difference in treatment 
outcomes (CD4 count and VL) between persons disclosed to will be done instead of 
disclosure vs non-disclosure. 
To whom disclosed to Frequency Percent Cumulative Percent 
Family, friends 14 28.00 28.00 
Family, partner 19 38.00 66.00 
Family or partner or pastor 7 14.00 80.00 
other 10 20.00 100.00 
Total 50 100.00  
a) Family or friends or Pastor or partner means a participant has disclosed to only one group 
of people or one person. b) Family/friends means a participant has disclosed to only two 
groups of people such as one or more members of the family and one or more friends. c) 
Family/partner means a participant has disclosed to only two groups of people such as one or 
more members of the family and/or a partner. d) Others mean that a participant has disclosed 
to more than two groups of people, which can either be family, friends, partner, employer, 
pastor and church. 
The comparison of the trends of CD4 counts and VL’s in five different time points, according 
to who they disclose to, was done using Analysis of Variance method. The chosen time 
points had sufficient sample sizes to do this comparison between treatment outcomes and 
who disclosed to categories in Table 4 above. The P-value of 0.1732 calculated from the test 
statistics concludes that, there is no statistically significant difference between CD4 counts 
and to whom disclose over time. 
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 Even for viral load comparison, we couldn’t find a statistically significant difference 
between the viral loads and to who disclosed to categories. Therefore, whether you disclose 
to your family, friends, pastor or church it does not make one better than the other on 
outcomes of treatment (drug adherence). Note that every participant in this study disclosed 
their HIV status therefore the comparison between disclosure and non-disclosure was not 
possible. Instead we compared the difference between treatment outcomes and the categories 
of which participants disclosed to. See figure 3 above and 4 below: 
Table 5 Mean log viral load count over the 5 time points 
Variable Observation Time 
points 
Mean Standard 
Deviation 
Minimum Maximum 
Logvl1 48 0 5.89495 4.059199 2.890372 14.91412 
Logvl2 43 1.1 4.270039 2.578309 2.995732 13.03054 
Logvl3 33 1.8 3.880572 2.068957 2.995732 10.81122 
Logvl4 24 2.6 3.490057 1.703258 2.995732 11.20601 
Logvl5 14 3.3 3.781037 1.700146 2.995732 9.191463 
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Figure 4: Mean log viral load to whom disclosed to 
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Table 6 Mean CD4 count over 5 time points 
Variable Observation Time points Mean Standard 
Dev. 
Minimum Maximum 
cd4cnt1 50 0 241.8 226.0201 2 930 
cd4cnt2 45 1.1 366.2667 250.3322 14 1307 
cd4cnt3 37 1.8 383.6757 216.5191 26 933 
cd4cnt4 31 2.6 400.9677 189.4442 31 901 
cd4cnt5 20 3.3 471 209.6144 36 831 
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Figure 5: Mean CD4 count to who disclosed to. 
The majority of respondents reported they disclosed because they needed support amongst 
other things. An overwhelming 82% reported they needed support while the remainder 
reported they disclosed because of counseling, education of others, prevention of 
transmission to others and their caregivers, encouraged uptake of VCT (voluntary counseling 
and testing). Some felt that HIV was just like any other disease, their family members died of 
the disease; saw many people taking HAART successfully. The other participants felt it was 
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necessary to disclose because their partners died of the disease and therefore it was public 
knowledge, while others wanted to be free and supported. 
The participants have reported varying responses after their HIV status disclosure, from being 
relieved to being rejected. The majority, about 78% felt relieved, accepted and supported, 8% 
felt supported, about 12% had mixed feelings, some felt free, hopeful and accepted. Only 2% 
of participants reported being rejected by a friend. 
Most of the respondents, 92%, believed that their families should know about their HIV 
positive status while only 8% were not comfortable with their families knowing their HIV 
status. The participants gave different reasons why they believed their families should know 
about their status. Some of the reasons included the following: 17.38% felt their disclosure 
would help prevent transmission during their care by family members, educating them about 
the disease and supporting other family members who were also HIV positive. The remaining 
82% believed disclosing their HIV status would earn them the much needed support to pull 
through their disease and treatment challenges. 
Of the 8% that did not disclose to their family members, 25% were not ready and 75% were 
afraid of stigma and discrimination. Disclosure to friends was accepted by 60% of 
respondents and the remaining 40% thought it was unimportant and unnecessary for friends 
to know. Those who responded yes to their friends knowing about their status, 6.66% of them 
said it was necessary to prevent transmission during care giving by their friends and to 
educate them about the disease. The 93.34% from this group believed the friends would give 
them support; they would feel free and felt there was no need to hide their status. 
Of those who did not disclose to friends, 5% claimed not to have friends, 10% felt it was not 
important, 5% thought friends would not help in anyway and 80% were afraid of stigma and 
discrimination. Regarding disclosure to their employers, 60% agreed that it was important for 
support so they would be allowed time to go for their treatment at the hospital, while 40% 
disagreed as they were afraid of stigma and discrimination. 
4.4. Antiretroviral Therapy 
The range of the participant’s initiation of therapy varies from 2002 to 2012. One percent 
started in 2002, fifty percent in 2010 and by 2012 ninety nine percent were already on 
treatment. The mean time of the start of treatment for the participants was 2008.96 with a 
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standard deviation of 2.28 and variance of 5.18. All participants have reported that they felt 
better since starting treatment. 
4.5. Drug Adherence 
46% of participants reported that they had skipped taking their medication at least once while 
54% of the participants reported that they had taken their medication religiously. Those that 
have skipped their medication gave various unique reasons why they skipped their medicines. 
Some participants said they missed their doses due to work related travel, forgot, were 
arrested for periods varying from three months to one year, some were involved in accidents, 
some thought they were healed. Other participants said they had medicine fatigue, some ran 
out of supply and a few have reported they missed their doses because they experienced drug 
side effects. 
Some participants reported experiencing drug side effects: 2% had hallucinations, 4% had 
lipodystrophy, 4% had pruritus and rash from co-trimoxazole (Bactrim®) and 20% had other 
unspecified side effects. A remaining 70% of participants were free from side effects. All 
participants reported not to have had the temptation to stop the medication at any stage of 
their treatment, regardless of having experienced some side effects. 
Table 7: Skipped medication vs to whom disclosed to 
 
Ever Skipped 
Medication? 
To whom disclosed to : 
Family, 
Friends 
 
Family, 
Partner 
Family or 
Partner or 
Pastor 
Other Total 
No 9 
64.29 
10 
52.63 
3 
42.86 
5 
50.00 
27 
54.00 
Yes 5 
35.71 
9 
47.37 
4 
57.14 
5 
50.00 
23 
46.00 
Total 14 
100.00 
19 
100.00 
7 
100.00 
10 
100.00 
50 
100.00 
The participants were asked if they had ever taken medicines in front of other people; 74% 
responded yes they had, for various reasons, and only 26% reported that they had never taken 
medicines in front of people. Of the 74% that took their medicines openly, 78.38% said it was 
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because they  had disclosed their HIV status, 2.7% said they did not care, 2.7% thought 
people should know and 16.22% said because people did not know the medication they were 
taking. Of the remaining 26% that had not taken their medicines openly, 30.77% of them said 
it was because they were always at home when taking their medicines, 7.69% indicated that 
they were afraid of stigma and discrimination while 61.54% said because they did not fully 
disclose their HIV status to people other than their family and partners 
Table 8 Hide taking medication among people vs to whom disclose to 
Hide taking 
medication 
among people 
To whom disclose to: 
Family, 
Friends 
Family, 
Partner 
Family or 
Partner or 
Pastor 
Other Total 
No 10 
71.43 
12 
63.16 
0 
0.00 
8 
80.00 
30 
60.00 
Yes 4 
28.57 
7 
36.84 
7 
100.00 
2 
20.00 
20 
40.00 
Total 14 
100.00 
19 
100.00 
7 
100.00 
10 
100.00 
50 
100.00 
Participants were also asked if they were hiding when taking medicines among people, and 
60% of participants were free to take their medicines openly while 40% were hiding their 
medicine when among people. Table 8 above shows that hiding medication among people 
does not depend on to whom disclose to. The Pearson chi-square p-value of 0.005 supports 
our conclusion. Table 8 also suggests that disclosing to more than one person helps not to 
hide taking medication in front of people.  All participants have reported that they were 
taking their medicines regularly. The research participants were also asked to give an opinion 
about the effect of disclosing the HIV status on taking their medicines, a resounding 98% 
agreed that disclosing ones HIV status would help improve taking antiretroviral therapy and 
only 2% disagreed. 
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CHAPTER FIVE 
5.1. Conclusion and Recommendations  
Some participants reported to have missed taking their medication; however the majority 
claimed that they were taking their medication regularly. The CD4count and the Viral load 
(VL) trends have corroborated the respondent’s claims as depicted by figures 1 and 2 
respectively. The CD4counts showed an upward trend while the VL showed a downward 
trend. 
The respondents disclosed to different people:  family, partner, friends and others. There was 
no statistically significant differences between to whom disclosed to over time on both the 
CD4 count and VL as shown in figure 3 and 4.Therefore, whether you disclose to either your 
family, friends, pastor or church does not make one better than the other on outcomes of 
treatment (drug adherence). 
It is apparent from the results that 82% (41) of the respondents have disclosed primarily 
because they needed support. 92% (46) believed that their families should know about their 
positive HIV status while only 8% (4) were not comfortable with their families knowing their 
HIV status. This is a very significant number and it puts the family at the epicenter of the 
strategy to improve drug adherence. 
Of the 8% that did not disclose to their family members, 25% (1) were not ready and 75% (3) 
were afraid of stigma and discrimination. 75% is quite significant; it highlights the fact that 
we still have challenges of stigma and discrimination to deal with. Disclosure to friends was 
accepted by 60% (30) of participants, and of these, 93.34% (28) believed it was necessary so 
that they could get support while taking their medication. 
Sixty-percent (30) of participants agreed that it was important to disclose to their employers, 
for support so that they will be allowed time to go for their treatment at the hospital, while the 
problem of stigma and discrimination has resurfaced again with 40% (20) not willing to 
disclose to their employers. 
Drug side effects played an insignificant role in the drug adherence in this study as 70% (35) 
of participants were free of side effects, 2% (1) experienced hallucinations, 4% (2) had 
lipodystrophy, 4%(2) had pruritus and rash from Bactrim (Co-trimoxazole) and 20%(10) had 
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other unspecified side effects. None of the participants reported any temptation to interrupt 
their treatment completely, despite having experienced some side-effects. 
The majority of participants (54%) 27 reported they had never skipped taking their 
medication. The participants also reported they had taken their medicine in front of other 
people and they constituted 74% (37) of the group. Of this 74%, 78.38% (29) said it was 
because they had disclosed their status. This observation supports the fact that if you have 
disclosed your HIV status, you are more likely to be adherent to treatment. In Table 7 it was 
shown that there was no statistically significant difference when you compare the ever 
skipped medicine by to who disclosed to. This observation further confirms the earlier 
statement that it does not matter whether you disclose to your family, friends, pastor or 
church; it does not make one better than the other as far as treatment outcomes (drug 
adherence) are concerned. The conclusion that one draws from this statement is that, for as 
long as you have disclosed, your outcomes of treatment adherence will be better. This 
observation is also supported by studies done by Mills et al, (2006), Nachega et al. (2004) 
and Nakiyemba et al., (2006) which supports the existence of a relationship between HIV 
status disclosure and drug adherence. 
Skhosana et al. (2006) hold a different view, they argue in their study conducted in 
Johannesburg that there was no direct relationship between disclosure of HIV status and 
adherence to ART. I believe they are bringing forward a weak case in their argument. They 
argue that the relationship between disclosure of HIV status and adherence to ART depends 
on the perception of both the patients and the person the information is disclosed to. This to 
me is an obvious straight forward case because any information whether related to HIV or 
not, for it to be interpreted, will depend on perceptions of the subjects involved and therefore 
you cannot use this argument to determine the relationship between two concepts. I agree 
with their view that fear of being stigmatized has been reported as a barrier to adherence to 
medication as this prevented patients from disclosing their HIV status and therefore losing 
their social support. This in my view confirms the existence of a relationship between HIV 
status disclosure and adherence to ART. 
Of the twenty six percent (13) participants that have not taken their medicines openly in front 
of other people, 30.77%(4) of them said it was because they were always at home when 
taking their medicines, 7.69%(1) indicated that they were afraid of stigma and discrimination 
while 61.54% (8) said because they did not fully disclose their HIV status to people other 
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than their family and partners. From the above facts, it can be argued that there is a clear 
relationship between HIV status disclosure and drug adherence. 
Sixty percent (30) of the participants said they were not hiding when taking medication 
among people, while 40% (20) were hiding. In table 8 it was shown that hiding medication 
among people does not depend on to who disclosed to. The Pearson chi-square p-value of 
0.005 supports our conclusion. Table 8 also suggests that disclosing to more than one person 
helps not to hide taking medication in front of people. All participants in the study have 
disclosed their HIV status and they all reported taking their medicines regularly. The patient’s 
CD4 count and VL were verified, the CD4 count has shown an upward trend while the VL 
load showed a downward trend in keeping with patients who are adhering to ART. 
These findings further support the argument that HIV status disclosure helps improve 
antiretroviral therapy adherence. All study participants agreed that disclosing HIV status does 
help improve their adherence to antiretroviral therapy. 
This study has two main shortcomings, the small sample size and the fact that all participants 
have disclosed their HIV status which makes it impossible to compare the outcomes of drug 
adherence in the patients who have not disclosed their HIV status. The small sample size of 
50 patients used in the study, poses a challenge because you cannot generalize results in 
confidence to the larger population from which the sample comes from. The lack of adequate 
resources also influenced the decision to use a small sample size. 
The larger significance of this study is to help highlight the importance of pre and posttest 
counseling. Counseling should also put emphasis on HIV status disclosure and ART drug 
adherence. Drug adherence counseling should be strengthened in all institutions that provide 
antiretroviral therapy. 
The lessons that were learned from this study would lead one to recommend that more 
research be done that would put more focus on counseling and drug adherence strategies. One 
other important recommendation is to resuscitate the almost dying public HIV/AIDS 
awareness campaigns to sensitize the communities to be more accepting and empathetic to 
people living with HIV/AIDS. These public awareness campaigns will heighten the fight 
against HIV/AIDS stigma and discrimination with a resultant effect of promoting HIV status 
disclosure and improved antiretroviral drug adherence. Voluntary counseling and testing 
campaigns must also be increased in communities. Mamelodi Hospital ART clinic must 
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spearhead and lead the public awareness campaigns so that the stigma and discrimination can 
be reduced leading to increased HIV status disclosure and better drug adherence. All these 
efforts contribute to the common goal of preventing HIV/AIDS spread and elimination of this 
pandemic. 
5.2. Guidelines 
All ART Clinics must put more emphasis on pre and posttest counseling. During counseling, 
the importance of HIV status disclosure and their relationship to drug adherence should be 
deliberately emphasized. All patients who seroconvert must be taught more about the coping 
mechanisms and strategies of how to best deal with stigma and discrimination. The public 
campaigns must be stepped up, and people must be informed about the plight of people living 
with HIV both infected and affected. The public must be taught more about the negative 
impact stigma and discrimination has on the lives of people living with HIV and how this can 
cause people to lose their lives. Drug Adherence counseling and education should be 
broadened to include all sectors of the communities even include other chronic illnesses so 
that HIV can also be taken as just another chronic conditions. 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
37 
 
References 
Ateka, G.K. (2006). HIV Status Disclosure and Partner Discordance: A Public Health 
Dilemma. Journal of the Royal Institute of Public Health. vol. 120, (pp. 493-496) 
John G. Bartlett, Joel B. Gallant, F. M. Conradie,(2008).Medical Management of HIV 
Infection. South African Edition, TheraSim, Inc. 
Buchan, I., Gill, C.J. and Cooper, C. (2006). Adherence to HAART: A Systemic Review of 
Developed and Developing Nation Patient-Reported Barriers and Facilitators. Public Library 
of Service medicine. Vol. 3, no. 11, (pp. 2039-2064). 
Jayne Byakika-Tusiime, Catherine Orrell, David Bangsberg, (2008).Global HIV/AIDS 
Medicine. (pp.207-213), Elsevier Inc. 
Larry B Christensen, R.Burke Johnson, Lisa A. Turner,(2011),Research Methods, Design , 
and Analysis. 11
th
 ed. Boston USA, Pearson, Inc. 
Klitzman, R.L., Kirshenbaum, S.B., Dodge, B., Remien, R.H., Ehrhardt, A.A., Johnson, 
M.O., Kittel, L.E., Daya, S., Morin, S.F., Kelly, J., Lightfoot, M. and Rotheram-Borus, M.J. 
(2004). The intricacies and inter-relationships between HIV disclosure and HAART: a 
qualitative study. AIDS Care, vol.16, no.5, (pp.629-637) 
Lévy, A., Laska, F., Abelhauser, A., Delfraissy, J.F., Goujard, C., Boué, F. and Dormont, J. 
(1999). Disclosure of HIV Seropositivity. Journal of Clinical Psychology, vol.55, no.9, (pp. 
1041-1043). 
Mills, E. J., Nachega, J.B., Bangsberg, D.R., Singh, S., Rachlis, B., Wu, P., Wilson, K., 
Nakiyemba, A., Aurugai, D.A., Kwasa, R. and Oyabba, T. (2006). Factors that Facilitate or 
Constrain Adherence to Antiretroviral Therapy among Adults in Uganda: A Pre-intervention 
Study. Geneva: World Health Organization. (pp. 249-301). 
Petrak, J.A., Doyle, A.M., Smith, A., Skinner, C. and Hedge, B. (2001). Factors Associated 
With Self-Disclosure of HIV Serostatus to Significant Others. British Journal of Health 
Psychology, vol.6, no.1, (pp. 69-79). 
Rabkin, M., El-Sadr, W. and Abrams, E. (2005). Care and Treatment of HIV/AIDS in 
Resource- Limited Settings. In: The Columbia Clinic Manual. New York: Mailman School of 
Public Health at Columbia University. (pp.264). 
Stellenbosch University  https://scholar.sun.ac.za
38 
 
Skhosana, N.L, Struther, H., Gray, G.E and McIntyre, J.A (2006). HIV Disclosure and Other 
Factors that Impact on Adherence to Antiretroviral Therapy: The Case of Soweto, South 
Africa. African Journal of AIDS Research, vol.5, no.1, (pp. 17-26). 
Spencer, D.C.(2005). The Clinical Practice of HIV Medicine, A practical guide to the care of 
the HIV infected. Johannesburg, South Africa. Goldstream Books. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
39 
 
Appendices 
Appendix A: Mamelodi Hospital Approval Letter 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
40 
 
 
Appendix B: Gauteng Health Department Approval Letter 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
41 
 
Appendix C:  Stellenbosch Approval Notice 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
42 
 
Appendix D: Consent Form 
Consent to participate in research 
TITLE OF THE STUDY: The effects of HIV status disclosure on antiretroviral therapy 
adherence. 
You are asked to participate in a research study conducted by DR MS PHALAFALA –BSc, 
MBCHB, PGDip (HIV/AIDS Management), from the Department of Economic and 
Management Science – Africa centre for HIV/AIDS management at Stellenbosch University.  
The results of the study will contribute to my research paper for my Master’s degree MPhil 
HIV/AIDS management.  You were selected as a possible participant in this study because 
you are over 18years of age, and have been on antiretroviral therapy for over 2years, which 
are the inclusion criteria for the study. 
1. PURPOSE OF THE STUDY 
The study is designed to establish the relationship and effects of HIV status disclosure to 
adherence to the antiretroviral therapy at Mamelodi Hospital. 
2. PROCEDURES 
If you volunteer to participate in this study, we would ask you to do the following things: 
You are going to be interviewed about the disclosure of your HIV status and how that 
affected your adherence to your antiretroviral medication. 
3. POTENTIAL RISKS AND DISCOMFORTS 
There are no risks expected during the study but you may suffer from the discomfort, as we 
will be asking you about your personal and private things regarding your HIV illness and 
how you are taking your medicines.  If the levels of your discomfort become too high, you 
will be referred for counselling. 
4. POTENTIAL BENEFITS TO SUBJECTS AND OR TO SOCIETY 
Subjects may or may not benefit directly from this study.  The study may benefit patients by 
empowering them with the new knowledge that will be obtained to assist in creating the 
necessary support structures for patients to adhere to antiretroviral therapy.  The overall 
benefit to patents is improved quality of life while on antiretroviral therapy.  The information 
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gathered from the study will contribute to the pool of knowledge that is available to prevent 
and treat HIV disease effectively. 
5. PAYMENT FOR PARTICIPATION 
Subjects or participants in the study will not be receiving any payment for their participation 
in the study. 
6. CONFIDENTIALITY 
Any information that is obtained in connection with this study and that can be identified with 
you will remain confidential and will be disclosed only with your permission or as required 
by Law.  Confidentiality will be maintained by means allocating participants with a study 
code number and the original coding list with participant’s name will be kept under lock and 
key by the researcher who will be the only person with access to the information.  If 
information will be released to any other party for any reason, it will be my study supervisor 
Mrs Riana Dippenaar, Stellenbosch University ethics review comity who will be assessing 
whether the study was done in accordance with the research ethics.  Stellenbosch University 
staff who will be marking my research study for purposes of my Master’s degree research 
paper. 
The results of the study will be published and all the information relating to the identity of the 
participants will be omitted on the publication. 
7. PARTICIPATION AND WITHDRAWAL 
You can choose whether to be in this study or not.  If you volunteer to be in this study, you 
may withdraw at any time without consequences of any kind.  You may also refuse to answer 
any question you do not want to answer and remain in the study.  The investigator may 
withdraw you from this research if circumstances arise which warrant doing so, for example 
if during the interview the subject becomes emotionally disturbed and becomes hysterical. 
8. IDENTIFICATION OF INVESTIGATORS 
If you have any questions or concerns about the research, please feel free to contact: 
Principal Investigator: DR M.S PHALAFALA. (012) 805 8080, Cell: 082 338 603, Email 
samp2@telkom.sa.net. 
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Supervisor: Mrs Riana Dippernaar, Email: riana.dippenaar@gmail.com 
University of Stellenbosch, Africa Centre for HIV/AIDS management, Administrative 
Assistant: Arlene Willets, Tel: 021 808 3405, Email: awillets@sun.ac.za 
9. RIGHTS OF RESEARCH SUBJECTS 
You may withdraw your consent at any time and discontinue participation without penalty.  
You are not waiving any legal claims, rights or remedies because of your participation in this 
research study.  If you have questions regarding your rights as a research subject, contact Ms 
Malene Fouche [mfouche@sun.ac.za, 021 808 4622] at the Division for Research 
Development. 
 
SIGNATURE OF RESEARCH SUBJECT OR LEGAL REPRESENTATIVE 
 
The information above was described to [me/the subject/the participant] by 
________________________ in Sotho/English/Zulu/Other] and [I am/the subject is / the 
participant is] in command of this language or it was satisfactorily translated to 
[me/him/her.].  [I /the participant/the subject] was given the opportunity to ask questions and 
these questions were answered to [my/his/her].  [I/the answered to [my/his/her] satisfaction. 
[I hereby consent voluntarily to participate in this study/I hereby consent that the 
subject/participant may participate in this study.] I have been given a copy of this form. 
_____________________________________ 
Name of Subject/ Participant 
_____________________________________ 
Name of Legal Representative (if applicable) 
______________________________________                             ___________________ 
Signature of Subject/Participant of Legal Representative        Date 
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SIGNATURE OF INVESTIGATOR 
 
I declare that I explained the information given in this document to ______________ [name 
of the subject/participant] and or [his/her] representative ______________________ [name 
of the representative.  [He/she] was encouraged and given ample time to ask me any 
questions.  This conversation was conducted in [Sotho/English/Zulu/Other] and [no translator 
was used/this conversation was translated into _____________by _____________]. 
_________________________________________________ 
Signature of Investigator______________________________ Date 
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Appendix E: Interview Protocol 
TITLE OF STUDY: The effects of HIV status disclosure on antiretroviral therapy adherence 
Participants No: 
Demographic Information 
Race: 
Gender: Male/Female 
Age: 
Sexual Orientation: 
 
HIV STATUS 
1. When you were first diagnosed with HIV? 
2. How were you diagnosed? –Voluntary/Involuntary 
3. Were you given Pre and Post-test counselling? 
4. Was Pre and Post Test counselling helpful? 
STATUS DISCLOSURE 
1. Have you disclosed your HIV status to anyone? Yes/No 
2.  
a. If yes, above to whom did you disclose to? 
b. Why did you disclose? 
c. Was the disclosure voluntary or involuntary? 
d. How did you feel after disclosure of your HIV status? 
3. If no at 1. above:- 
a. Are you planning to disclose?  Yes/ No 
b. Why are you not disclosing? 
(Fear of discrimination, Stigma, Isolation). 
4. Do you think your family should know about your illness? Yes/No 
If yes, why? 
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If no, why? 
5. Do you think your friends and should know about your illness? Yes/No 
If yes, why? 
If no, why? 
6. Do you think your school/employer should know about your illness? Yes/No 
ANTIRETROVIRAL THERAPY 
1. When did you start taking antiretroviral medication? 
2. Do you feel better on medication? Yes/No 
3. Have you ever suffered any drug side effects? 
- If yes, have you ever felt the need to stop taking your medication? Yes/No 
- If no, have you ever felt the need to stop taking your medication? Yes/No 
4. Have you ever skipped your medication? Yes/No 
- If yes, why did you skip the medication? 
5. Have you ever taken your medicine in front of other people? Yes/No 
- If yes, why? 
- If no, why? 
6. Do you hide taking your medication when among people? 
7. Do you take your medicine regularly? 
8. Do you think disclosing your HIV status will help improve taking your medication? 
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Appendix F: Revised Who Clinical Staging of Hiv/Aids for Adult and Adolescents 
(Interim African Region version for persons aged 15 years or more with positive HIV 
antibody test of other laboratory evidence of HIV infection) 
Table1.  Revised WHO CLINICAL STAGING OF HIV/AIDS AND ADOLESCENT 
Primary HIV Infection 
Asymptomatic 
Acute retroviral syndrome 
 
Clinical stage 1 
Asymptomatic 
Persistent generalized lymphadenopathy (PGL) 
 
Clinical stage 2 
Asymptomatic 
Persistent generalized lymphadenopathy (PGL) 
 
Clinical stage 3 
Severe weight loss (>10 % of presumed measured body weight) 
Unexplained chronic diarrhoea for longer than one month 
Unexplained persistent fever (intermittent of constant for longer than one month) 
Oral candidiasis 
Oral hairy leukoplakia 
Pulmonary tuberculosis (TB) diagnosed in two years 
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Server presumed bacterial infections (e.g. pneumonia, empyema, pyomosistis, bone or joint 
infection, meningitis, bacteraemia) 
Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
Conditions where confirmatory diagnostic testing is necessary 
Unexplained anaemia (<8 g/dl), and or neutropenia (<500/mm3) and or thrombocytopenia 
(<50 000/ mm3) for more than one month 
All clinical events or conditions referred to all described in the Annexes.  The UN defines 
adolescents as persons aged 10 – 19 years but, in the present documents, the category of 
adults and adolescents comprises people aged 15 years and over for surveillance purposes. 
 
Clinical stages 4 
Conditions where a presumptive diagnosis can be made on the basis of clinical signs or 
simple investigations 
HIV wasting syndrome 
Pneumocystis pneumonia 
Recurrent severe or radiological bacterial pneumonia 
Chronic herpes simplex infection (oralabial, genital or anorectal of more than one month’s 
dration) 
Oesophageal candidiasis 
Extrapulmonary TB 
Kaposi’s sarcoma 
Central nervous system (CNS), toxoplasmosis 
HIV encephalopathy 
Conditions where confirmatory diagnostic testing is necessary: 
Extrapulonary cryptococcosis including meningitis 
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Disseminated non- Mycobacteria turberculous infection 
Progessive multifocal leukeoncephalopathy (PML) 
Candida of trachea, bronchi or lungs 
Cytomegalovirus (CMV) infection (retinitis or of an organ other than liver, spleen or lymph 
nodes) 
Any disseminated mycosis (e.g. histoplasmosis , coccidiomycosis, penicilliosis) 
Recurrent non-typhoidal salmonella septicaemia 
Lympnoma (cerebal or B cell non-Hodgkin) 
Invasive cervical carcinoma 
Visceral leishmaniasis 
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Appendix G:  Antiretroviral Therapy Guidelines 
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